P. Andrew Futreal
University of Texas MD Anderson Cancer Center
350 Papers
1K Citations
P. Andrew Futreal is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Biology & Medicine. The author has an hindex of 107, co-authored 245 publications. Previous affiliations of P. Andrew Futreal include Wellcome Trust & Wellcome Trust Sanger Institute.
Chat about Author
Papers
Genomic profiling of multifocal intrahepatic cholangiocarcinoma reveals intraindividual concordance of genetic alterations.
Sung Hwan Lee,E. Simoneau,Tatiana Karpinets,P. Andrew Futreal,Jianjun Zhang,Milind Javle,Jianhua Zhang,Jean Nicolas Vauthey,Ju Seog Lee,Jeannelyn S. Estrella,Yun Shin Chun +10 more
TL;DR: In this cohort of multifocal IHC, genomic profiles were concordant across all tumors in each patient, suggesting a common progenitor cell origin, regardless of the location of tumors in the liver.
Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases.
Preeti Kanikarla Marie,Cara Haymaker,Edwin R. Parra,Young Uk Kim,Rossana Lazcano,Swati Gite,Daniele Lorenzini,Ignacio I. Wistuba,Rebecca S. S. Tidwell,Xiaofei Song,Wai Chin Foo,Dipen M. Maru,Yun Shin Chun,P. Andrew Futreal,Bryan K. Kee,David G. Menter,Luisa M. Solis,Ching Wei D. Tzeng,Christine Megerdichian Parseghian,Kanwal Pratap Singh Raghav,Van K. Morris,Chia-Chi Chang,Robert R. Jenq,Alda L. Tam,Chantale Bernatchez,Scott Kopetz,Jean Nicolas Vauthey,Michael J. Overman +27 more
TL;DR: In this article, the authors explored combining anti-CTLA-4 and anti-PD-L1 therapy in the preoperative management of resectable colorectal cancer liver metastases with the intent to improve immune responses in this disease setting.
Protection against fibrosis by a bacterial consortium in metabolic dysfunction-associated steatohepatitis and the role of amino acid metabolism
Suet Ying Kwan,Kristyn A Gonzales,Mohamed A Jamal,Heather L Stevenson,Lin Tan,Philip L. Lorenzi,P. Andrew Futreal,Ernest T Hawk,Joseph B McCormick,Susan P. Fisher-Hoch,Robert R Jenq,Laura Beretta +11 more
TL;DR: A bacterial consortium from Bacteroidales and Clostridiales orders protects against liver fibrosis in metabolic dysfunction-associated steatohepatitis by modulating amino acid metabolism, specifically increasing cysteine synthase activity and altering tryptophan-to-kynurenine conversion.
Data mining using the Catalogue of Somatic Mutations in Cancer BioMart.
Rebecca Shepherd,Simon A. Forbes,David Beare,Sally Bamford,Charlotte G. Cole,Sari Ward,Nidhi Bindal,Prasad Gunasekaran,Mingming Jia,Chai Yin Kok,Kenric Leung,Andrew Menzies,Adam Butler,Jon W. Teague,Peter J. Campbell,Michael R. Stratton,P. Andrew Futreal +16 more
TL;DR: The data available in COSMIC is described along with examples of how to successfully mine and integrate data sets using COS MICMart, and a flexible way to mine these data and combine somatic mutations with other biological relevant data sets is provided.
Genome Sequencing and Analysis of the Tasmanian Devil and Its Transmissible Cancer
Elizabeth P. Murchison,Ole Schulz-Trieglaff,Zemin Ning,Ludmil B. Alexandrov,Markus J. Bauer,Beiyuan Fu,Matthew M. Hims,Zhihao Ding,Sergii Ivakhno,Caitlin Stewart,Bee Ling Ng,Wendy S.W. Wong,Bronwen Aken,Simon D. M. White,Amber E. Alsop,Jennifer Becq,Graham R. Bignell,R. Keira Cheetham,William Cheng,Thomas R. Connor,Anthony J. Cox,Zhi-Ping Feng,Zhi-Ping Feng,Yong Gu,Russell J. Grocock,Simon R. Harris,Irina Khrebtukova,Zoya Kingsbury,Mark Kowarsky,Alexandre Kreiss,Shujun Luo,John Marshall,David J. McBride,Lisa Murray,Anne-Maree Pearse,Keiran Raine,Isabelle Rasolonjatovo,Richard Shaw,Philip Tedder,Carolyn Tregidgo,Albert J. Vilella,David C. Wedge,Gregory M. Woods,Niall Anthony Gormley,Sean Humphray,Gary P. Schroth,Geoffrey Paul Smith,Kevin Hall,Stephen M. J. Searle,Nigel P. Carter,Anthony T. Papenfuss,Anthony T. Papenfuss,P. Andrew Futreal,Peter J. Campbell,Fengtang Yang,David R. Bentley,Dirk J. Evers,Michael R. Stratton +57 more
TL;DR: Genomic analysis suggests that the cancer first arose from a female Tasmanian devil and that the clone has subsequently genetically diverged during its spread across Tasmania.